Clinical trials focusing on PTLD
| Clinical trial identifier . | Title of the study . | Role in PTLD . | Target population . |
|---|---|---|---|
| NCT03266653 | EBV-specific cytotoxic T-lymphocytes (CTLs) for refractory EBV infection | Preventive | Children and adults |
| NCT05183490 | R-MVST cells for treatment of viral infections | Preventive | Adults |
| NCT04989491 | Evaluation of the efficacy of a treatment by one single dose of rituximab (375mg/m2) in the prevention of the EBV primary infection and posttransplant lymphoproliferative disorder in adult EBV seronegative patients who received an EBV seropositive kidney allograft (REPLY) | Preventive | Adults |
| NCT04507477 | Ex-vivo delivery of rituximab to prevent PTLD in EBV mismatch lung transplant recipients: a pilot trial | Preventive | Adults |
| NCT02580539 | A study of the safety and efficacy of EBV specific T-cell lines (EBV-TCL-01) | Preventive or frontline | Adults |
| NCT02900976 | Rituximab and LMP-specific T-cells in treating pediatric solid organ recipients with EBV-positive, CD20-positive posttransplant lymphoproliferative disorder | Frontline | Children and adults |
| NCT04337827 | Rituximab and acalabrutinib in newly diagnosed B-cell posttransplant lymphoproliferative disorder | Frontline | Adults |
| NCT04554914 | A study to evaluate tabelecleucel in participants with EBV–associated diseases | Frontline | Children and adults |
| NCT05786040 | Tafasitamab and rituximab for front-line treatment of posttransplant lymphoproliferative disorder | Frontline | Adults |
| NCT01192464 | EBV CTLs expressing CD30 chimeric receptors for CD30+ lymphoma (CARCD30) | Frontline or relapsed | Children and adults |
| NCT03131934 | Immunotherapy with tacrolimus resistant EBV CTL for lymphoproliferative disease after solid organ transplant (ITREC) | Frontline or relapsed | Children and adults |
| NCT05011058 | An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with EBV+ relapsed/refractory lymphomas (NAVAL-1) | Relapsed | Adults |
| NCT03394365 | Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant participants with EBV-associated posttransplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy (ALLELE) | Relapsed | Children and adults |
| NCT04664179 | EBV-specific T-lymphocytes for treatment of EBV+ lymphoma (CILESTE) | Relapsed | Children and adults |
| NCT04925544 | Clinical trial of a novel small molecule EBNA1 inhibitor, VK 2019, in patients with EBV+ nasopharyngeal cancer (NPC) and other EBV-associated cancers, with pharmacokinetic and pharmacodynamic correlative studies | Relapsed | Adults |
| NCT05714748 | Application of mRNA immunotherapy technology in EBV-related refractory malignant tumors | Relapsed | Adults |
| NCT02287311 | Most closely matched 3rd party rapidly generated LMP, BARF1 and EBNA1 specific CTL, EBV+ lymphoma (MABEL) | Relapsed | Children and adults |
| Clinical trial identifier . | Title of the study . | Role in PTLD . | Target population . |
|---|---|---|---|
| NCT03266653 | EBV-specific cytotoxic T-lymphocytes (CTLs) for refractory EBV infection | Preventive | Children and adults |
| NCT05183490 | R-MVST cells for treatment of viral infections | Preventive | Adults |
| NCT04989491 | Evaluation of the efficacy of a treatment by one single dose of rituximab (375mg/m2) in the prevention of the EBV primary infection and posttransplant lymphoproliferative disorder in adult EBV seronegative patients who received an EBV seropositive kidney allograft (REPLY) | Preventive | Adults |
| NCT04507477 | Ex-vivo delivery of rituximab to prevent PTLD in EBV mismatch lung transplant recipients: a pilot trial | Preventive | Adults |
| NCT02580539 | A study of the safety and efficacy of EBV specific T-cell lines (EBV-TCL-01) | Preventive or frontline | Adults |
| NCT02900976 | Rituximab and LMP-specific T-cells in treating pediatric solid organ recipients with EBV-positive, CD20-positive posttransplant lymphoproliferative disorder | Frontline | Children and adults |
| NCT04337827 | Rituximab and acalabrutinib in newly diagnosed B-cell posttransplant lymphoproliferative disorder | Frontline | Adults |
| NCT04554914 | A study to evaluate tabelecleucel in participants with EBV–associated diseases | Frontline | Children and adults |
| NCT05786040 | Tafasitamab and rituximab for front-line treatment of posttransplant lymphoproliferative disorder | Frontline | Adults |
| NCT01192464 | EBV CTLs expressing CD30 chimeric receptors for CD30+ lymphoma (CARCD30) | Frontline or relapsed | Children and adults |
| NCT03131934 | Immunotherapy with tacrolimus resistant EBV CTL for lymphoproliferative disease after solid organ transplant (ITREC) | Frontline or relapsed | Children and adults |
| NCT05011058 | An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with EBV+ relapsed/refractory lymphomas (NAVAL-1) | Relapsed | Adults |
| NCT03394365 | Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant participants with EBV-associated posttransplant lymphoproliferative disease (EBV+ PTLD) after failure of rituximab or rituximab and chemotherapy (ALLELE) | Relapsed | Children and adults |
| NCT04664179 | EBV-specific T-lymphocytes for treatment of EBV+ lymphoma (CILESTE) | Relapsed | Children and adults |
| NCT04925544 | Clinical trial of a novel small molecule EBNA1 inhibitor, VK 2019, in patients with EBV+ nasopharyngeal cancer (NPC) and other EBV-associated cancers, with pharmacokinetic and pharmacodynamic correlative studies | Relapsed | Adults |
| NCT05714748 | Application of mRNA immunotherapy technology in EBV-related refractory malignant tumors | Relapsed | Adults |
| NCT02287311 | Most closely matched 3rd party rapidly generated LMP, BARF1 and EBNA1 specific CTL, EBV+ lymphoma (MABEL) | Relapsed | Children and adults |
R-MSVT, rapidly generated multivirus-specific T cells.